The report discusses the safety and market factors of autologous versus allogeneic regenerative cell therapies, emphasizing that both types are manipulated and require thorough safety assessments. It highlights the advantages of allogeneic therapies in terms of convenience and cost.
documents/EFTA01143480.pdf
{}